Artificial Pancreas Device Systems Market (2024 - 2030)

Market Size & Trends

The global artificial pancreas device systems (APDS) market was valued at USD 289.9 million in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 18.9% between 2024 and 2030. Market expansion is primarily driven by the rising incidence of Type 1 diabetes, intensified research and development initiatives by pharmaceutical companies, and the growing demand for automated glycemic control systems.

Artificial pancreas device systems are designed to regulate blood glucose levels in diabetic patients. These systems are comparatively less invasive and have achieved broad patient adoption. Growth is further supported by the increasing geriatric population, the rising global prevalence of diabetes, and the escalating incidence of obesity.

Technological progress in continuous glucose monitoring (CGM) systems and insulin pump technologies has significantly improved the accuracy, reliability, and clinical outcomes of APDS. Additionally, greater awareness of their effectiveness in diabetes management and complication prevention has accelerated adoption. Government initiatives and reimbursement frameworks across multiple regions are enhancing both accessibility and affordability, thereby expanding the patient base. The aging population, being more vulnerable to diabetes, continues to drive sustained demand for these medical devices.

The digital transformation of healthcare is also expected to stimulate market growth. For example, wearable technologies for Type 2 diabetes patients enable real-time monitoring of vital parameters and provide actionable insights for disease management. The surging demand for wearables is creating new commercial opportunities, positioning digitalization as a key enabler of innovation and market expansion.

Furthermore, the shift toward personalized therapies and the integration of artificial intelligence (AI) into healthcare systems are fostering the development of next-generation APDS solutions. However, high device costs, along with cybersecurity and ethical concerns, may act as constraints on future market penetration.

 

Device Type Insights

In 2023, threshold suspend device systems dominated the market, accounting for 73.8% of total share. Their leadership is attributed to safety features that automatically suspend insulin delivery when glucose levels fall below a predefined threshold, thereby reducing the risk of hypoglycemia. These systems were the first automated insulin delivery devices to receive regulatory approval in multiple countries. They are particularly beneficial during sleep or periods when patients cannot respond to hypoglycemia, and their operational simplicity has further strengthened adoption.

The Control-to-Target (CTT) systems segment is projected to record the fastest CAGR of 21.3% during the forecast period. This growth is driven by their advanced and precise glucose management capabilities, which help maintain blood glucose within a target range while minimizing hypoglycemia risk. Continuous improvements in sensor technology, algorithm design, and insulin delivery mechanisms are enhancing system accuracy and usability. Moreover, the integration of AI-driven analytics is accelerating innovation and positioning CTT systems as the next frontier in automated diabetes management.

Report Coverage & Deliverables

Regional Insights

North America artificial pancreas device systems market dominated with a share of 45.8% in 2023. The high prevalence of diabetes in the region, advanced healthcare infrastructure, patient awareness, and increasing investments in research and development under public-private partnerships boost regional developments. The major market players and their distribution networks contribute to the availability of artificial pancreas device systems across the region.

U.S. Artificial Pancreas Device Systems Market Trends

The U.S. artificial pancreas device systems market dominated North America in terms of revenue share in 2023 due to the increasing demand in the geriatric population for advanced diabetes management solutions. The rising prevalence of diabetes and technological advancements in glucose monitoring systems and insulin pumps add to the exponential growth.

Europe Artificial Pancreas Device Systems Market Trends

Europe artificial pancreas device systems market was identified as a lucrative region in 2023. The market is growing due to the rise in geriatric population with a high prevalence of diabetes. A well-established healthcare system and government policies that support diabetes management encourage the demand for automated systems and devices.

The UK artificial pancreas device systems market is expected to grow in the coming years due to patient awareness and demand for more effective diabetes management solutions. The focus on research, medical technology, and a higher adoption rate of advanced diabetes management solutions further enlarge the market share.

Asia Pacific Artificial Pancreas Device Systems Market Trends

Asia Pacific artificial pancreas device systems market is anticipated to witness significant growth in the forecast period. The rising healthcare expenditure, strong healthcare infrastructure, and growing awareness among the population for advanced diabetes management solutions. In addition, the region’s large population and increasing disposable income are expected to fuel the market demand.

Japan artificial pancreas device systems market is expected to grow rapidly in the coming years due to the country's increasing aging population. The rising incidence of diabetes among the elderly population drives the need for clinical devices. The advanced healthcare infrastructure and a strong emphasis on technological advancement are increasing the demand for market expansion.

India artificial pancreas device systems market held a substantial market share in 2023 owing to the high prevalence of diabetes in the population. Moreover, the rising use of digital health monitoring devices is pivotal for market developments. The growing awareness among patients about advanced diabetes management solutions is driving the market growth.

Key Artificial Pancreas Device Systems Company Insights

Some key companies in the artificial pancreas device systems market include Medtronic Plc, Bigfoot Biomedical, Tandem Diabetes Care, Inc., TypeZero Technologies, LLC, and others.

• Medtronic Plc is a global medical technology company that provides services and solutions. The company is known for the MiniMed series of insulin pumps integrated with continuous glucose monitoring (CGM) systems. This advanced hybrid closed loop series automatically adjusts insulin delivery based on CGM reading.

• Pancreum, Inc. is a medical device company that focuses on developing advanced diabetes management. The company emphasizes creating modular artificial pancreas systems to provide a more flexible and customizable approach to insulin delivery.

Key Artificial Pancreas Device Systems Companies:

The following are the leading companies in the artificial pancreas device systems market. These companies collectively hold the largest market share and dictate industry trends.

• Medtronic Plc
• Bigfoot Biomedical
• Tandem Diabetes Care, Inc.
• Pancreum, Inc.
• TypeZero Technologies, LLC
• Beta Bionics

Recent Developments

• In July 2024, Tandem Diabetes Care Inc. introduced the updated insulin pump software, t:slim X2, compatible with Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems with Health Canada as the authorized distributor.

Artificial Pancreas Device Systems Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 343.5 million
Revenue forecast in 2030	USD 981.0 million
Growth Rate	CAGR of 18.9% from 2024 to 2030
Base year for estimation	2023
Historical data	2018 - 2022
Forecast period	2024 - 2030
Quantitative units	Revenue in USD million and CAGR from 2024 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Device type, region
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Germany; UK; France; Italy; Spain; China; Japan; India; South Korea; Australia; Brazil; Colombia; Mexico; Argentina; UAE; Saudi Arabia: South Africa
Key companies profiled	Medtronic Plc; Bigfoot Biomedical; Tandem Diabetes Care, Inc.; Pancreum, Inc.; Type Zero Technologies, LLC; Beta Bionics; Advanced Micro Devices
Customization scope	Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs.

Global Artificial Pancreas Device Systems Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global artificial pancreas device systems market report based on device type and region.

• Device Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Threshold Suspend Device Systems

  • Control-to-Range (CTR) Systems

  • Control-to-Target (CTT) Systems

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East and Africa (MEA)

    • UAE

    • South Africa

    • Saudi Arabia